Introduction

Our increased understanding of the complexity of cancer has revealed a wide number of therapeutic targets, against which a diverse range of therapeutic strategies are required. Consequently, the repertoire of cancer drug discovery approaches has expanded significantly beyond the identification of traditional small molecule catalytic inhibitors or functional blocking antibodies.  

This conference will explore a breadth of new technical approaches to the identification and development of novel cancer therapeutics, including agents in early clinical development. The aim is to provide an accessible insight into recent developments in this rapidly evolving field, that aims to harness our insights from cancer research for the benefit of patients.

Register now

Target audience

Scientists in academia and industry who are interested in the most recent developments in cancer therapeutic discovery, including small molecule, degrader, peptide, and antibody technologies. The conference will include several novel antitumour approaches in early clinical development.

Topics to be covered:

• Degrader approaches (PROTACs and molecular glues)
• Antibody drug conjugates (ADCs)
• Oral cyclic peptide inhibitors
• Targeting RAS and mutant p53
• Strategies for identifying small molecule hits (phenotypic and covalent fragment screens)

Scientific Programme Committee

• Steve Wedge, Cancer Research Horizons Therapeutic Innovation and Newcastle University, UK (Chair)
• Susan Critchlow, AstraZeneca, Cambridge, UK
• Erica Jackson, Scorpion Therapeutics, Boston, USA
• Mark Pearson, Boehringer-Ingelheim, Austria
• Georg Winter, CeMM, Austria